Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy1. A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene2. Human melanoma expresses Bcl-2 in up to 90% of all cases3–7. In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemo-sensitivity of human melanoma grown in severe combined im-munodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Boring, C.C., Squires, T.S., Tong, T. & Montgomery, S. Cancer statistics 1994. CA: Cancer J. Clinic 44, 7–26 (1994).
Hickman, J.A. Apoptosis and chemotherapy resistance. Eur. J. Cancer 32A, 921–926 (1996).
Cerroni, L., Soyer, H.P. & Kerl, H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatopathol. 17, 7–11 (1995).
Morales-Ducret, C.R.J., van deRijn, M., LeBrun, D.P. & Smoller, B.R. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 131, 909–918 (1995).
Plettenberg, A. et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am. J. Pathol. 146, 651–659 (1995).
Tron, V.A. et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol. 146, 643–650 (1995).
Grover, R. & Wilson, C.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 22, 347–349 (1996).
Stein, C.A. & Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents–Is the bullet really magical? Science 261, 1004–1012 (1993).
Stein, C.A. Does antisense exist? Nature Med. 1, 1119–1121 (1995).
Christoffersen, R.E. Translating genomics information into therapeutics: A key role for oligonucleotides. Nature Biotechnol. 15, 483–484 (1997).
Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675 (1996).
Comis, R.L. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep. 60, 165–176 (1976).
Henry, S.P., Monteith, D. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligonucleotides. Anti-Cancer Drug Des. 12, 395–408 (1997).
Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).
Wooldridge, J.E., Ballas, Z., Krieg, A.M. & Weiner, G.J. Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89, 2994–2998 (1997).
Webb, A. et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137–1141 (1997).
About this article
Cite this article
Jansen, B., Schlagbauer-Wadl, H., Brown, B. et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4, 232–234 (1998). https://doi.org/10.1038/nm0298-232
New insights into the roles of antiapoptotic members of the Bcl-2 family in melanoma progression and therapy
Drug Discovery Today (2021)
Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Current Drug Targets (2020)
Critical Reviews in Oncology/Hematology (2019)
Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs